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Abstract
Background: Hypothyroidism is one of the most common endocrine disorders, whereas symmetrical onychomadesis
is a rare claw disease in the general dog population. The aims of this study were to estimate the prevalence of
hypothyroidism and symmetrical onychomadesis in a birth cohort of 291 Gordon setters at eight years of age.
Further, to describe the age at diagnosis of hypothyroidism in the 68 Gordon setters and 51 English setters
included in the DLA study. Finally, to elucidate potential associations between dog leukocyte antigen (DLA)
class II and hypothyroidism and/or symmetrical onychomadesis in the Gordon setter and the English setter.
Results: In the birth cohort of eight years old Gordon setters, 2.7 % had hypothyroidism and 8.9 % had
symmetrical onychomadesis, but only one out of these 291 dogs (0.3 %) had both diseases. Mean age at
diagnosis of hypothyroidism for dogs included in the DLA study was 6.4 years (95 % CI: 5.6-7.2 years) in the
Gordon setters and 7.7 years (95 % CI: 7.2-8.2 years) in the English setters. The DLA alleles most associated
with hypothyroidism in the Gordon setter and English setter were DLA-DQB1*00201 (OR = 3.6, 95 % CI: 2.1-6.4,
p < 0.001) and DLA-DQA1*00101 (OR = 2.9, 95 % CI: 1.3-6.6, p < 0.001), respectively.
In the Gordon setter, the haplotype DLA-DRB1*01801/DQA1*00101/DQB1*00802 was significantly associated
with both symmetrical onychomadesis (OR = 2.9, 95 % CI: 1.7-5.2, p < 0.001) and with protection against
hypothyroidism (OR = 0.3, 95 % CI: 0.2-0.5, p < 0.001).
Conclusion: Hypothyroidism is a complex disease where DLA genes together with other genes may be
involved in the pathogenesis of the disease. In the Gordon setter, one DLA haplotype that was associated
with protection against hypothyroidism was also associated with symmetrical onychomadesis. These findings
indicate that closely linked genes, instead of or together with the DLA genes themselves, may be associated
with hypothyroidism and symmetrical onychomadesis. In a breed where several autoimmune diseases are
prevalent all possible associations between DLA genes and actual diseases need to be investigated before
DLA is considered used as a tool for marker-assisted selection.
Lay summary
An autoimmune disease occurs when the body’s immune
system attacks normal cells of the body. For instance an
autoimmune attack on the thyroid gland may cause
hypothyroidism in both dogs and humans. Thyroid hor-
mones are involved in several energy demanding processes
in the body and subnormal hormone levels in dogs may
cause a variety of clinical signs such as dullness, weight
gain, lethargy, and skin changes. Dogs with compatible
signs of hypothyroidism are commonly diagnosed based
on subnormal levels of thyroid hormones and elevated
levels of thyroid stimulating hormone (TSH) in serum.
Symmetrical onychomadesis is an acute claw disease
where the dogs lose all claws during 3–4 months. The
disease is known to occur in Gordon setters and many
other dog breeds. Hypothyroidism and symmetrical ony-
chomadesis appear to be more common in some dog
breeds than others like the Rhodesian Ridgeback and the
Giant Schnauzer. High prevalence of one disease in one
dog breed could indicate that genetic factors contribute
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to disease development. In a birth cohort of Norwegian
Gordon setters at eight years, the prevalence of
hypothyroidism was 2.7 % and the prevalence of sym-
metrical onychomadesis was 8.9 % (n = 291). The
Gordon setters and the English setters were middle aged
when they were diagnosed with hypothyroidism.
Dog leukocyte antigen (DLA) genes play an essential
role in the immune response and they have been associ-
ated with different autoimmune diseases in dogs. In this
study, different DLA haplotypes and alleles were associ-
ated with hypothyroidism in the Gordon setter and the
English setter. In the Gordon setter, one DLA haplotype
that may protect against hypothyroidism may concur-
rently predispose dogs to symmetrical onychomadesis.
All possible immune mediated diseases in one breed
needs to be investigated for associations to DLA before
information about DLA is considered used as a tool for
marker-assisted selection to reduce disease prevalence.
Background
Hypothyroidism is one of the most common endocrine
diseases reported in dogs [1]. In most cases, the disease
is considered to be the result of an autoimmune attack
of the thyroid gland [2]. It is still debated whether the
lymphocytic form of hypothyroidism is the first stage
and the atrophic form is the end stage of the disease, or
if they are two different diseases entities [2–4]. Subclin-
ical hypothyroidism is characterised by the presence of
autoantibodies against thyroglobulin (TgAA) in serum
and elevated serum TSH values [2–4] with lymphocytic
infiltrates in the thyroid gland [4]. In dogs with overt
hypothyroidism, more than 75 % of the functional gland
is destroyed and blood chemistry is characterised by the
presence of TgAA, elevated TSH, and in most cases de-
creased free thyroxin/total thyroxin (FT4/TT4) levels
[2–4]. End stage or atrophic form of hypothyroidism is
characterised by absence of TgAA in serum, normal or
elevated TSH, and decreased FT4/TT4 levels [2, 3]. The
gland now has a non- inflammatory and an atrophic ap-
pearance on histopathology [4]. Hypothyroidism is con-
sidered to be a disease of middle aged dogs, but age
at diagnosis has been reported to differ between
breeds [4]. The age at diagnosis may also depend on
the stage of hypothyroidism hence dogs with TgAA-
positive hypothyroidism are in general younger than
dogs with TgAA-negative hypothyroidism [2, 3].
Diagnosing hypothyroidism in dogs can be a challenge
due to confusing blood results and vague clinical signs
[2]. TSH, as a diagnostic test for hypothyroidism, has
high specificity but low sensitivity in dogs [5]. A high
TSH value is therefore well suited to confirm a diagnosis
of hypothyroidism, but a normal TSH value cannot ex-
clude hypothyroidism [5, 6]. Autoantibodies may also
falsely increase TT4 and FT4 levels in serum when TT4
and FT4 are measured by chemiluminescense [7]. More-
over, dogs suffering from other critical diseases or severe
chronic illnesses may have low TT4 values without hav-
ing hypothyroidism (euthyroid sick syndrome) [8, 9].
These diagnostic aspects are important to consider when
collecting cases and controls for genetic studies of
hypothyroidism.
Autoimmune hypothyroidism is a multifactorial disease
in which many genetic and environmental factors are as-
sumed to affect disease development and disease outcome
[2]. Comparably higher prevalences of hypothyroidism in
the English setter, the Giant Schnauzer, and the Hovawart
indicate an accumulation of genetic variants in these
breeds [10, 11]. Research on autoimmune hypothyroidism
in human patients indicates that genetic factors contribute
to as much as 70-80 % to the risk of developing the dis-
ease [12, 13]. The major histocompatibility complex
(MHC) class II has been associated with various auto-
immune diseases in both humans and dogs [14, 15]. In
dogs, genes coding for this complex are named DLA. The
DLA class II genes comprise three highly polymorphic
and closely linked genes, DLA-DRB1, DLA-DQA1, and
DLA-DQB1 [16]. In the Doberman Pinscher, the Rho-
desian Ridgeback and the Giant Schnauzer associations
between specific DLA class II haplotypes/alleles and
hypothyroidism have been described [17–20]. In the
Gordon setter and the Giant Schnauzer associations be-
tween specific DLA class II haplotypes/alleles and sym-
metrical onychomadesis have been reported [21].
Common clinical signs of hypothyroidism in dogs in-
clude weight gain, mental dullness, and lethargy [3]. Other
signs of the disease are hypothermia and poor hair coat
quality with skin changes, such as alopecia, hyperkeratosis,
and seborrhea [3, 4]. In humans, detached nails from the
nail bed (onycholysis) has been described in hypothyroid
patients [22]. Claw changes in dogs with hypothyroidism
are uncommon [23]. Symmetrical onychomadesis is a claw
disease where the dogs lose all their claws within a few
months [24]. Both symmetrical onychomadesis and
autoimmune hypothyroidism occur with high preva-
lence in Giant Schnauzers, German Shepherds and
Rhodesian Ridgebacks [21, 23]. Mueller et al. sug-
gested that these diseases may share genetic risk fac-
tors since they both occur with high prevalence in
the same breeds, although not necessarily in the same
dog [24, 25].
The aims of this study were to: 1) Investigate the
prevalence of hypothyroidism and symmetrical onycho-
madesis in a large birth cohort of Gordon setters; 2) De-
scribe the age at diagnosis of hypothyroidism in the
Gordon setter and English setter; 3) To investigate poten-
tial associations between DLA class II haplotypes/alleles
and hypothyroidism and/or symmetrical onychomadesis in
the Gordon setter and the English setter.
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Results
Epidemiology of hypothyroidism and symmetrical
onychomadesis
The prevalence of hypothyroidism in eight years old
Gordon setters was 2.7 % (95 % CI: 1.3-5.1 %, n = 291).
The prevalence of symmetrical onychomadesis in the
same study population was 8.9 % (95 % CI: 6.0-12.6 %).
Only one of these 291 dogs had both hypothyroidism
and symmetrical onychomadesis.
From the DLA study the Gordon setters comprised 68
cases and 93 controls and the English setters comprised
83 cases and 53 controls. The age at diagnosis, median
TSH-, TT4-, FT4- and cholesterol values at time of diag-
nosis in cases are presented in Table 1. The mean age of
the control dogs together with their median TSH-, TT4-,
FT4- and cholesterol values are also presented in Table 1.
TgAA analysis was not performed in all cases because
it was not available at the time of samples collection.
Thus only, 31 out of 151 hypothyroid dogs were
tested for TgAA and 114 out of 146 controls were
tested for TgAA (Table 1). Five of the controls had
positive TgAA titers but these dogs were still included as
controls because none of them developed clinical or bio-
chemical signs of hypothyroidism during their life time.
Medical records of symmetrical onychomadesis were
obtained in retrospect from 83.2 % of the Gordon set-
ters and English setters participating in the DLA study
(n = 297). Among the hypothyroid Gordon setters
21.1 % of these dogs had symmetrical onychomadesis
(n = 57) and 5.6 % of the hypothyroid English setters
had symmetrical onychomadesis (n = 53). In Gordon
setters without hypothyroidism, 22.2 % of these dogs
had symmetrical onychomadesis (n = 91) and 2.1 % of
the English setters without hypothyroidism had sym-
metrical onychomadesis (n = 47) (Table 1).
DLA haplotypes and alleles associated with
hypothyroidism in the Gordon setter and the English
setter
Ten DLA haplotypes were present in the Gordon setter
population (n = 161), and seven DLA haplotypes were
present in the English setter population (n = 136). Five
DLA haplotypes occurred in both breeds (Tables 2 and 3).
A complete overview of DLA allele frequencies in the
Gordon setters and the English setters are given in
Additional file 1: Tables S1and S2. The haplotype, DLA-
DRB1*00103/DQA1*00101/DQB1*00201 was present in
8.3 % of the Gordon setters and found to be associated
Table 1 Gordon setters and English setters in the DLA study
Cases Controls
GS (n = 68) ES (n = 83) GS (n = 93) ES (n = 53)
Sex and age
Male 22 42 57 33
Female 46 41 36 20
Age (y): mean
(95 % CI)
6.4 (5.6-7.2) 7.7 (7.2-8.2) 9.3 (9.0-9.7) 8.8 (8.3-9.3)
Range age, years 1.8-12.9 2.7-15 8-14.4 8-16
Analysis blood samples
TSH ug/L: median (range) 3.01 (0.46-12.0) 2.24 (0.46-12.0) 0.14 (0.03-0.45) 0.23 (0.04-0.45)
TT4 nmol/L: 7.5 (4.0-77.0) 6.0 (4.0-44.0) 28.0 (16.0-53.0) 24.0 (16.0-45)
median (range)
FT4 pmol/L: 9.0 (4.0-65.0) 7.0 (4.0-77.0) 14.0 (7.0-69.0) 14.0 (7.0-47.0)
median (range)
Cholesterol mmol/L: 9.1 (2.6-20.8) 11.7 (3.4-23.1) 6.1 (3.6-11.0) 5.8 (3.8-11.0)
median (range)
TgAA positive (n) 14 6 4 1
TgAA negative (n) 2 8 59 45
TgAA inconclusive (n) 0 1 0 5
Diagnosis of SO
positive (n) 12 3 20 1
negative (n) 45 50 70 46
TSH thyroid stimulating hormone (reference values: 0–0.45 ug/L), TT4 total thyroxin (Reference values: 16–46 nmol/L), FT4 free thyroxine (reference values: 7–44
pmol/L). cholesterol: (reference values: 3.4-10.0 mmol/L). TgAA thyroglobulin autoantibodies
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with hypothyroidism in this breed (OR = 4.4, 95 % CI: 1.8-
11.5, p < 0.001) (Table 4). Only five Gordon setters were
homozygous for this haplotype, three cases and two con-
trols. The more common haplotype among the Gordon
setters, DLA-DRB1*04901/DQA1*01001/DQB1*01901 was
also associated with hypothyroidism (OR = 2.1, 95 % CI:
1.2-3.7, p = 0.008) (Table 4).
In the English setter the haplotype DLA-DRB1*00
107/DQA1*00101/DQB1*00201 was associated with
hypothyroidism (OR = 2.0, 95 % CI: 1.1-3.8, p = 0.01)
(Table 5). Seven cases were homozygous, whereas none of
the controls were homozygous for this haplotype. The allele
DLA-DQA1*00101 was present in 89.3 % of the English
setters and was found to be associated with hypothyroidism
(OR = 2.9, 95 % CI: 1.3-6.6, p = 0.002) (Table 5).
DLA- DQA1*00101 was also the most common allele
in the Gordon setter, however, it was not associated
with hypothyroidism in this breed. In the Gordon setter
this allele was instead part of the most common and also
protective haplotype DLA-DRB1*01801/DQA1*00101/
DQB1*00802 (OR = 0.3, 95 % CI: 0.2-0.5, p < 0.001)
(Table 4). Notably, DLA- DQB1*00201 was associated
with hypothyroidism in both the Gordon setter (OR = 3.6,
95 % CI: 2.1-6.4, p < 0.001) and the English setter (OR =
1.9, 95 % CI: 1.1-3.3, p = 0.03). It is also worth noting that
77.6 % of the English setters and 21.4 % of the Gordon set-
ters carried the allele DLA- DQB1*00201 (Tables 4 and 5).
Three Gordon setter cases and 19 controls were
homozygous for the most common DLA haplotype in
this breed (DLA-DRB1*01801/DQA1*00101/DQB1*00802).
Thus, homozygosity for this DLA haplotype was associated
with the strongest protection for hypothyroidism in the
Gordon setter (OR = 0.2, 95 % CI: 0.1-0.6, p = 0.004). Eight-
een Gordon setter cases and 41 controls were heterozy-
gous for this haplotype (DLA-DRB1*01801/DQA1*00101/
DQB1*00802) (OR = 0.51, 95 % CI: 0.29-0.98, p = 0.04).
Haplotype DLA-DRB1*01801/DQA1*00101/DQB1*0
0802 was absent in the English setter. The only DLA
haplotype associated with protection for hypothyroidism in
the English setter was DLA-DRB1*00601/DQA1*005011/
DQB1*00701 (OR = 0.22, 95 % CI: 0.03-0.81, p = 0.02).
Only nine English setters (3.3 %) and none of the Gordon
Table 2 DLA haplotypes in the Gordon setter
All GS GS cases GS controls GS cases/ GS controls
DLA-haplotype % n = 322 % n = 136 % n = 186 OR CI 95 % p-value
DRB1*01801/DQA1*00101/DQB1*00802 31.9 103 18.3 25 41.9 78 0.3 0.2-0.5 0.000006
DRB1*01501/DQA1*00601/DQB1*02301 5.9 19 2.2 3 8.6 16 0.2 0.1-0.8 0.001
DRB1*00103/DQA1*00101/DQB1*00201 8.3 27 14.7 20 3.7 7 4.4 1.8-11.5 0.0005
DRB1*00101/DQA1*00101/DQB1*00201 11.1 36 15.4 21 8.0 15 2.1 1.03-4.28 0.04
DRB1*02001/DQA1*00401/DQB1*01303 11.4 37 11.0 15 11.8 22 n.s
DRB1*04901/DQA1*01001/DQB1*01901 18.9 61 25.7 35 13.9 26 2.1 1.2-3.7 0.008
DRB1*00901/DQA1*00101/DQB1*008011 7.4 24 6.6 9 8.0 15 n.s
DRB1*00501/DQA1*00301/DQB1*00501 0.9 3 1.4 2 0.5 1 n.s
DRB1*00107/DQA1*00101/DQB1*00201 1.8 6 3.6 5 0.5 1 n.s
DRB1*01501/DQA1*00601/DQB1*00301 1.8 6 0.7 1 2.6 5 n.s
Cases; Gordon setter with hypothyroidism, Controls; Gordon setters without hypothyroidism, n.s; non significant, OR; Odd ratio, CI; confidence interval
Table 3 DLA haplotype in the English setter
All ES ES cases ES controls ES cases/ES controls
DLA-haplotype % n = 272 % n = 166 % n = 106 OR CI 95 % p-value
DRB1*01501/DQA1*00601/DQB1*02301 2.1 5 0.6 1 3.8 4 n.s
DRB1*00101/DQA1*00101/DQB1*00201 52.9 144 52.4 87 53.8 57 n.s
DRB1*02001/DQA1*00401/DQB1*01303 4.0 11 3.6 6 4.7 5 n.s
DRB1*00901/DQA1*00101/DQB1*008011 11.7 32 11.4 19 12.3 13 n.s
DRB1*00601/DQA1*005011/DQB1*00701 3.3 9 1.2 2 6.6 7 0.2 0.03-0.8 0.02
DRB1*00107/DQA1*00101/DQB1*00201 24.6 67 29.5 49 17.0 18 2.0 1.1-3.8 0.01
DRB1*03802/DQA1*00901/DQB1*00101 1.4 4 1.3 2 1.8 2 n.s
Cases; English setters with hypothyroidism, Controls; English setters without hypothyroidism, n.s; non significant, OR; Odd ratio, CI; confidence interval
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setters had this haplotype. All alleles in the haplotype
DLA-DRB1*00601/DQA1*005011/DQB1*00701 were
unique to that haplotype.
DLA haplotypes associated with symmetrical
onychomadesis in the Gordon setter and the English
setter
The haplotype DLA- DRB1*01801/DQA1*00101/DQB1*00802
has previously been associated with symmetrical ony-
chomadesis in the Gordon setter [21] which was con-
firmed in the present study (Additional file 1: Table S3).
Nine out of 12 Gordon setters with symmetrical ony-
chomadesis and hypothyroidism were also heterozygous
for this haplotype (DLA- DRB1*01801/DQA1*00101/
DQB1*00802). Only three English setters had both
symmetrical onychomadesis and hypothyroidism; one
was homozygous for DLA- DRB1*00107/DQA100101/
DQB1*00201, one was homozygous for DLA-DRB1*00
101/DQA1*00101/DQB1*00201 and one was heterozy-
gous with the preceding haplotypes.
Discussion
Gordon setters and English setters are frequently used
as hunting dogs and both hypothyroidism and symmet-
rical onychomadesis reduce their hunting abilities be-
sides welfare concerns [26]. The true breed prevalence
of hypothyroidism is challenging to determine. In this
study, a large sample from a birth cohort of Gordon set-
ters was investigated at eight years of age. The preva-
lence of hypothyroidism was 2.7 %. This estimate was
based on dogs that were examined by a veterinarian be-
cause of their owners’ suspicion of hypothyroidism. The
prevalence may therefore be underestimated because
some owners misinterpret the signs of hypothyroidism
as normal signs of getting old and hence do not seek
medical care. The estimated prevalence of 8.9 % of
Gordon setters affected with symmetrical onychomad-
esis is in accordance with previous published results
[26]. The prevalence for hypothyroidism and symmet-
rical onychomadesis in the English setters could not be
estimated in the present study, but this breed has been
described as a high- risk breed for hypothyroidism in
previous studies [3, 4]. Only four of the English setters
in this study had symmetrical onychomadesis. The
prevalence of symmetrical onychomadesis in the
English setter is thought to be lower than that observed
in the Gordon setter [26].
Overall, 50 % of hypothyroid dogs have TgAA positive
hypothyroidism, but the frequencies of TgAA positive
hypothyroidism vary among breeds [3]. This could suggest
that different genetic factors affect disease development
in various breeds [2, 3]. Graham et al. discovered that 61
out of 73 English setters (84 %) had TgAA positive
hypothyroidism, while for instance only 13 out of 81
Dachshunds (16 %) were TgAA positive [3]. Graham et al.
also discovered that dogs diagnosed with TgAA positive
hypothyroidism in general were younger than dogs diag-
nosed with TgAA negative hypothyroidism [3]. In our
study, English setters were relatively old when they were
diagnosed with hypothyroidism, but since neither TgAA
measurements nor biopsies of the thyroid gland were avail-
able for all the dogs in this present study, it cannot be de-
termined if they had the atrophic form of hypothyroidism
or a late form of TgAA-positive hypothyroidism.
DLA has been associated with several different im-
mune mediated diseases in dogs [27–29]. The most
Table 4 DLA-haplotypes and alleles associated with hypothyroidism or protection against hypothyroidism in the Gordon setter
Total Cases Controls Cases/controls
DLA-haplotype or allele % n = 322 % n = 136 % n = 186 OR 95 % CI p-value
DRB1*00103/DQA1*00101/DQB1*00201 8.3 27 14.7 20 3.7 7 4.4 1.8 - 11.5 0.0005
DLA-DQB1*00201 21.4 69 33.8 46 12.4 23 3.6 2.1 - 6.4 0.000005
DRB1*04901/DQA1*01001/DQB1*01901 18.9 61 25.7 35 13.9 26 2.1 1.2 - 3.7 0.008
DRB1*00101/DQA1*00101/DQB1*00201 11.1 36 15.4 21 8.0 15 2.1 1.0 - 4.3 0.04
DRB1*01801/DQA1*00101/DQB1*00802 31.9 103 18.3 25 41.9 78 0.3 0.2 - 0.5 0.000006
DRB1*01501/DQA1*00601/DQB1*02301 5.9 19 2.2 3 8.6 16 0.2 0.1 - 0.8 0.001
Table 5 DLA-haplotypes and alleles associated with hypothyroidism or protection against hypothyroidism in the English setter
Total Cases Controls Cases/Controls
DLA-haplotype or allele % n = 272 % n = 166 % n = 106 OR CI 95 % p-value
DRB1*00107/DQA1*00101/DQB1*00201 24.6 67 29.5 49 17.0 18 2.0 1.1-3.8 0.01
DLA-DQA1*00101 89.3 243 93.4 155 83.0 88 2.9 1.3-6.6 0.002
DLA-DQB1*00201 77.6 211 81.9 136 70.8 75 1.9 1.1-3.3 0.03
DRB1*00601/DQA1*005011/DQB1*00701 3.3 9 1.2 2 6.6 7 0.2 0.03-0.8 0.02
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common DLA haplotype in the Gordon setter (DLA-
DRB1*01801/DQA1*00101/DQB1*00802) in this study
was associated with protection for hypothyroidism, and
interestingly, this DLA haplotype was also reported asso-
ciated with symmetrical onychomadesis in the same
breed. The fact that the same DLA haplotype is associ-
ated with one autoimmune disease and also associated
with protection for another presumed autoimmune dis-
ease, clearly suggests that specific combinations of DLA
alleles do not necessarily predispose dogs for auto-
immune diseases in general. It also indicates that poten-
tial functional effects of autoimmune disease may be
associated to closely linked loci to DLA-haplotypes. The
allele DLA-DQA1*00101 was both associated with
hypothyroidism in the English setter and part of a haplo-
type associated with protection of hypothyroidism in the
Gordon setter. Several hypothyroidism protective DLA
haplotypes occurred at a high frequency in the Gordon
setter, whereas such protective DLA haplotypes were
rare in the English setter. Another DLA haplotype asso-
ciated with protection of hypothyroidism (DLA-
DRB1*01301/DQA1*00301/DQB1*00501) has been
reported from the Giant Schnauzer [20], but this haplo-
type was not observed among our Gordon setters or
English setters. One previously reported DLA haplotype
associated with hypothyroidism in the Giant Schnauzer
and the Doberman (DLA-DRB1*01201/DQA1*00101/
DQB1*00201) [18, 20] contained two of the most com-
mon alleles associated with hypothyroidism in English
setter (DLA-DQA1*00101, DQB1*00201). The DLA-
DQB1*00201 was also associated with hypothyroidism in
the Gordon setter. This allele together with DLA-
DQA1*00101 has also previously been reported associ-
ated with symmetrical onychomadesis in the Gordon
setter [21]. Kennedy et al. suggested that the DLA-
DQA1*00101 allele is associated with hypothyroidism in
many breeds [17]. The findings of different DLA associa-
tions with hypothyroidism in different breeds are con-
sistent with previous findings of different HLA
associations with hypothyroidism observed both within
and between ethnic groups in humans [15].
Conclusions
The Gordon setters had a prevalence of 2.7 % of
hypothyroidism and 8.9 % of symmetrical onychomadesis.
Both the Gordon setters and the English setters were mid-
dle aged when they were diagnosed with hypothyroidism.
One allele (DLA- DQB1*00201) was associated with
hypothyroidism in both the Gordon setter and the English
setter. Another allele (DLA- DQA1*00101) was associated
with hypothyroidism in the English setter, but not in the
Gordon setter. The same haplotype (DLA-DRB1*01801/
DQA1*00101/DQB1*00802) was associated both with
symmetrical onychomadesis and with protection against
hypothyroidism in the Gordon setter. At the moment the
functional genes in hypothyroidism and symmetrical ony-
chomadesis are not known. The opposite effects of some
alleles/haplotypes on two different autoimmune diseases
may indicate that closely linked genes to DLA genes are
involved. Further studies are needed to investigate how
DLA genes or other closely linked genes participate in the
pathogenesis of hypothyroidism and symmetrical onycho-
madesis. It is also important to state that selection of
breeding animals supported by DLA haplotypes/alleles
could only be used if taking into account also poten-
tial associations to other autoimmune disorders in a
dog breed as well as how it influence the genetic
variation in that breed.
Methods
Epidemiology of hypothyroidism and symmetrical
onychomadesis
Gordon setters eight years of age received a health survey
in 2012 (n = 474). Non-responders were followed up by
telephone interview. The response rate was 61 % (n = 291).
Dogs with reported hypothyroidism and/or symmetrical
onychomadesis were confirmed by an evaluation of veter-
inary records. All dogs with hypothyroidism (n = 8) fulfilled
the diagnostic criteria: TSH >0.45 μg/L, TT4 ≦16 nmol/L,
and FT4≦8 pmol/L. Symmetrical onychomadesis cases
were dogs with one or multiple episodes of onychomadesis
during their lifetime (n = 26).
Cases and controls for the DLA study were collected
between 2006 and 2012. Cases were analysed for serum
values of TSH, TT4, FT4, and cholesterol (Table 1).
Cases were dogs with clinical signs of hypothyroidism
with serum TSH > 0.45 μg/L and at least one of the fol-
lowing diagnostic criteria; TT4 < 16 nmol/L and/or
TT4 > 46 nmol/L, FT4 < 7 pmol/ and/ or FT4 > 44
pmol/L and/or cholesterol > 10 mmol/L and/or positive
TgAA analysis. Controls were dogs eight years or
older without signs of hypothyroidism and the follow-
ing serum levels: TSH ≦ 0.45 μg/L, TT4 > 15 nmol/L,
FT4 > 6 pmol/L, and cholesterol < 11 mmol/L (Table 1).
The reference values at the Central laboratory was;
TSH = 0–0.45 ug/L, TT4 = 16–46 nmol/L, FT4 = 7–44
pmol/L, cholesterol: 3.4-10.0 mmol/L. All dogs were
screened for relatedness and showed no indication of
a closer relationship than the general population in
these breeds.
Blood analysis
Serum levels of TSH, TT4, and FT4 were analysed on an
IMMULITE® 2000 XPi Immunoassay System (Siemens
Healthcare Diagnostics, Siemens AG, Germany). In the
present study, two chemiluminescent assays for measur-
ing free T4 in canine serum were used. Initially, an assay
primarily evaluated for analyzing free T4 in human sera
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was used (IMMULITE® 2000 Free T4). However, this
assay has been evaluated for canine samples [30]. When
IMMULITE® 2000 Veterinary Free T4 became available
this assay was preferred and calibrated to use identical
reference intervals as related to the previous method for
healthy and hypothyroid dogs. Most of the serum sam-
ples were analysed within five days, but a few samples
had been kept frozen at −20 °C before they were ana-
lysed. Storage of serum samples at −20 °C should not
interfere with serum TT4 and FT4 levels [31]. Analysis
of TgAA antibodies was not available at the Central La-
boratory until March, 2009. The presence of TgAA was
determined by an indirect enzyme immunoassay using
microplates containing both thyroglobulin coated (Tg+)
and non-specific binding (Tg-) strips (Oxford Laborator-
ies, Inc., Oxford, MI, USA) and an microplate absorb-
ance reader (Tecan Sunrise™, Tecan Group Ltd.,
Switzerland) reading the absorbance at 450 nm for each
well. The values for the non-specific binding wells were
subtracted from the corresponding positive and negative
sera. Then the average of the non-specific binding wells
was subtracted from the average of each sample. Each
sample was divided by the corrected positive reference
serum and multiplied by 100. Samples > 25 % of the
positive reference serum are positive for TgAA, samples
below 10 % are negative and samples from 10 to 25 %
are inconclusive (“grey zone”) for TgAA.
DLA class II genotyping
DLA-DRB1, DLA-DQA1, and DLA-DQB1 exon 2 DNA
sequences were obtained from 161 Gordon Setters and
136 English Setters. DNA was extracted using E.Z.N.A®
blood DNA kit and then PCR amplified. One PCR reac-
tion mixture contained 1.5 μl aliquots of the DNA solu-
tion, 0.05 μl HotStarTaq Master Mix (Qiagen GmbH),
0.5 μl of each forward and reverse DLA-specific primer
(20 pmol; Eurofins MWG Operon) (see Additional file
1: Table S4), 1.5 μl dNTP (2.5 mM; Amplicon), 1.5 μl
PCR Buffer (Qiagen), 1 μl Q-Solution (Qiagen), and
8.45 μl distilled water. PCR reactions were carried out
in a Veriti® Thermal Cycler Applied Biosystems using
the following PCR protocol: initial Hot Start at 95 °C
for 15 min; 14 touch down cycles of 95 °C for 30 s,
followed by 1 min annealing, starting at 62 °C (DLA-
DRB1), 54 °C (DLA-DQA1), 73 °C (DLA-DQB1) and
reducing by 0.5 °C each cycle, and 72 °C for 1 min; then
20 cycles of 95 °C for 30 s, 55 °C (DLA-DRB1), 47 °C
(DLA-DQA1) 66 °C (DLA-DQB1) for 1 min, 72 °C for
1 min; and final extension at 72 °C for 10 min. PCR
products were separated on 1 % agarose gel and visual-
ized under UV light after staining with ethidium brom-
ide to check for appropriately sized products, and
subsequently purified using the Illustra™ Exostar™
clean-up kit (GE Healthcare). Sequencing reaction
mixtures were prepared using BigDye® Terminator v3.1
Cycle Sequencing Kit (Thermo Fisher Scientific) and
the samples were then sequenced on a 3500xL Genetic
Analyzer (Applied Biosystems). PCR products were ini-
tially sequenced in one direction, but if the DLA allele
could not be completely determined the opposite direc-
tion was sequenced as well. All DNA sequences were fi-
nally analysed and alleles were designated for each
sequence using MatchTools and MatchToolsNavigator
(Applied Biosystems). Alleles not present in the built-in
allele library were identified by a BLAST search [32].
Statistical analyses
Standard deviations and confidence intervals for means
were calculated using Microsoft Excel 2011. In
hypothyroid dogs, the standard deviations were all
greater than half of the mean for the TSH, TT4 and FT4
values. This strongly indicated that the thyroid values
were skewed and therefore the median values with range
were reported instead of the mean with standard devi-
ation [33]. Two by two contingency tables were used to
evaluate association between DLA-DRB1/DQA1/DQB1
haplotypes and individual DLA alleles. Odd ratio (OR)
were calculated using the web-based statistical calculator
in OpenEpi 3.01. Chi-square test was used and two-tail
mid-p exact values were calculated. A 95 % confidence
level was used for all tests.
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